ReviewAdvances in neurobiology2025
Role of Oligodendrocyte Lineage Cells in White Matter Injury.
Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter provides a comprehensive review of white matter injuries, with a particular focus on oligodendrocyte lineage cell-mediated mechanisms and strategies. Traumatic mechanical insults, vascular conditions, perinatal injuries, and degenerative diseases all have white matter components and can be studied using different animal models. These distinct etiologies converge on similar pathophysiological features comprised of programmed cell death of oligodendrocyte lineage cells, demyelination, release of myelin debris, ion imbalance, excitotoxicity, mitochondrial dysfunction, and Wallerian degeneration. Therapeutics that target oligodendrocyte lineage cells are warranted due to their role in remyelination, immunomodulation, circuit remodeling, and maintenance of vasculature. Thus, emerging diagnostic techniques can help in assessing the extent of oligodendrocyte lineage cell-related pathology, while regenerative treatments, including cell transplantation, endogenous cell mobilization, biomaterials, and rehabilitation, can facilitate recovery by driving regeneration of oligodendrocyte lineage cells and myelin. Despite tremendous progress in this field, the heterogeneity of oligodendrocyte lineage cells suggests that a personalized medicine approach may optimize recovery following injury.
Indexed as
Identifiers
40500502What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.